eXoZymes (EXOZ) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed eXoZymes (EXOZ) over the past year, losing 62.6% versus a loss of 81.8%. eXoZymes is the larger company by market cap ($27.4 million vs $21.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | MGX |
|---|---|---|
| Share price | $2.91 | $0.565 |
| Market cap | $27.42M | $21.36M |
| 1-day change | -14.05% | -7.95% |
| YTD return | -73.35% | -65.12% |
| 1-year return | -81.84% | -62.58% |
| EPS (TTM) | $-1.16 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $25.21M |
| Revenue growth (YoY) | — | -51.79% |
| Net income (latest FY) | $-9.16M | $-87.87M |
| Operating margin | — | -380.85% |
| Net margin | — | -348.54% |
| 52-week high | $16.16 | $1.87 |
| 52-week low | $2.81 | $0.562 |
| Distance from 52-week high | -82.02% | -69.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | — | +1138.94% |
| Average volume | 10.14K | 163.21K |
| Shares outstanding | 9.44M | 37.81M |
| Employees | 32 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed EXOZ by 19.3 percentage points over the past year.
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
EXOZ vs MGX FAQ
Which is bigger, eXoZymes or Metagenomi Therapeutics?
eXoZymes (EXOZ) is larger, with a market capitalization of $27.42M compared with $21.36M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, EXOZ or MGX?
MGX returned -62.58% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.